- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07650448
WATER IV PCa (AS Sub-study)
WATER IV Prostate Cancer: Aquablation Versus Active Surveillance for the Treatment of Localized Prostate Cancer
The WATER IV study is a multicenter, prospective, randomized clinical trial that aims to evaluate the safety and efficacy of Aquablation therapy in men with localized prostate cancer.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The WATER IV AS sub-study is a multicenter, prospective, randomized clinical trial that aims to evaluate the safety and efficacy of Aquablation therapy in men with low to intermediate risk localized prostate cancer who are candidates for active surveillance. Participants will be randomized to either Aquablation Therapy or active surveillance and followed up to 10 years.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Angela Lee
- Telefonnummer: 650-232-7215
- E-post: a.lee@procept-biorobotics.com
Studiesteder
-
-
Arizona
-
Chandler, Arizona, Forente stater, 85224
- Har ikke rekruttert ennå
- Arizona State Urological Institute
-
Hovedetterforsker:
- Pratik Patel, MD
-
Ta kontakt med:
- Dianna Baldanado
- E-post: dbaldonado@asuri.net
-
-
California
-
Los Angeles, California, Forente stater, 90089
- Rekruttering
- University of Southern California
-
Hovedetterforsker:
- Inderbir Gill, MD
-
Hovedetterforsker:
- Mihir Desai, MD
-
Ta kontakt med:
- Ileana Aldana
- Telefonnummer: (323) 865-0702
- E-post: Nohely.Aldana@med.usc.edu
-
Murrieta, California, Forente stater, 92562
- Har ikke rekruttert ennå
- Tri Valley Urology
-
Ta kontakt med:
- Anita Deeds
- Telefonnummer: 232 951-698-1901
- E-post: anita@trivalleyurology.net
-
-
Colorado
-
Boulder, Colorado, Forente stater, 80304
- Har ikke rekruttert ennå
- Boulder Medical Center
-
Ta kontakt med:
- Stephanie Leonard
- E-post: sleonard@westernstatesncorp.org
-
-
Florida
-
Delray Beach, Florida, Forente stater, 33484
- Rekruttering
- Advanced Research
-
Hovedetterforsker:
- Christopher Tallman, MD
-
Ta kontakt med:
- Julia Conceição
- Telefonnummer: (954)-302-3163
- E-post: jconceicao@advancedresearchfl.com
-
Miami, Florida, Forente stater, 33146
- Har ikke rekruttert ennå
- University of Miami
-
Hovedetterforsker:
- Bruno Nahar, MD
-
Ta kontakt med:
- Laura Ochoa
- E-post: lxo315@med.miami.edu
-
Tampa, Florida, Forente stater, 33607
- Har ikke rekruttert ennå
- Trophy Point Urology
-
Ta kontakt med:
- Zachary Finley
- E-post: zfinley@floridaurologypartners.com
-
Hovedetterforsker:
- Timothy Weber, MD
-
Underetterforsker:
- Jonathan Pavlinec, MD
-
Underetterforsker:
- David Hochberg, MD
-
Underetterforsker:
- Drew Palmer, MD
-
Underetterforsker:
- Sam Fisher, MD
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30328
- Rekruttering
- Georgia Urology
-
Hovedetterforsker:
- Lewis Kriteman, MD
-
Ta kontakt med:
- Cyprian Adi
- Telefonnummer: 404-292-3727
- E-post: Cyprian.adi@gaurology.com
-
Underetterforsker:
- Froylan Gonzalez, MD
-
-
Idaho
-
Idaho Falls, Idaho, Forente stater, 83401
- Rekruttering
- Mountain View Hospital
-
Ta kontakt med:
- Morgann Torres
- E-post: mtorres1@mvhospital.net
-
Hovedetterforsker:
- Jared Manwaring, MD
-
Underetterforsker:
- Richard Blatter, MD
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- Har ikke rekruttert ennå
- University of Chicago
-
Ta kontakt med:
- Briana Harrison
- E-post: bharrison1@bsd.uchicago.edu
-
Glenview, Illinois, Forente stater, 60026
- Rekruttering
- Endeavor Health
-
Underetterforsker:
- Alexander Glaser, MD
-
Ta kontakt med:
- Pooja Talaty
- E-post: pooja.talaty@endeavorhealth.org
-
Hovedetterforsker:
- James Kearns, MD
-
Underetterforsker:
- Brian Helfand, MD
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Har ikke rekruttert ennå
- Johns Hopkins University
-
Hovedetterforsker:
- Arun Rai, MD
-
Ta kontakt med:
- George Metri
- E-post: gmetri1@jh.edu
-
Underetterforsker:
- Arvin George, MD
-
-
Missouri
-
North Kansas City, Missouri, Forente stater, 64116
- Har ikke rekruttert ennå
- Kansas City Urology Care
-
Ta kontakt med:
- Judy Searcy
- Telefonnummer: 913-647-4173
- E-post: jsearcy@kcuc.com
-
Hovedetterforsker:
- Gerald Park, MD
-
Underetterforsker:
- Patrick Probst, MD
-
-
Nebraska
-
Kearney, Nebraska, Forente stater, 68847
- Rekruttering
- Kearney Urology Center
-
Hovedetterforsker:
- Garrett Pohlman, MD
-
Ta kontakt med:
- Monique Pohlman
- E-post: water4trialkearneyurology@gmail.com
-
Omaha, Nebraska, Forente stater, 68114
- Rekruttering
- Adult & Pediatric Urology
-
Hovedetterforsker:
- Andrew Trainer, MD
-
Ta kontakt med:
- Christian Valverde
- E-post: cvalverde@urohealthpartners.com
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Har ikke rekruttert ennå
- Hackensack University Medical Center
-
Hovedetterforsker:
- Nitin Yerram, MD
-
Ta kontakt med:
- Oncology Clinical Research Referral Office
- Telefonnummer: 551-996-1777
- E-post: OncologyResearchReferral@hmhn.org
-
Underetterforsker:
- Ravi Munver, MD
-
-
New York
-
Albany, New York, Forente stater, 12208
- Har ikke rekruttert ennå
- Albany Medical College
-
Hovedetterforsker:
- Ronald Kaufman, MD
-
Ta kontakt med:
- Brenda Romeo
- Telefonnummer: (518) 262-8579
-
New York, New York, Forente stater, 10016
- Rekruttering
- Integrated Medical Professionals, PLLC
-
Hovedetterforsker:
- Jed Kaminetsky, MD
-
Hovedetterforsker:
- Alexander Epelbaum, MD
-
Hovedetterforsker:
- Gary Goldberg, MD
-
Ta kontakt med:
- Michael Yang
- E-post: myang@imppllc.com
-
Rochester, New York, Forente stater, 14642
- Har ikke rekruttert ennå
- University of Rochester Medical Center
-
Ta kontakt med:
- Caitlyn Michelsen
- E-post: Caitlyn_Michelsen@URMC.Rochester.edu
-
Hovedetterforsker:
- Thomas Frye, MD
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Har ikke rekruttert ennå
- Cleveland Clinic Foundation
-
Hovedetterforsker:
- Petar Bajic, MD
-
Ta kontakt med:
- Lauren Grimm
- Telefonnummer: 216-444-4650
- E-post: grimml@ccf.org
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Rekruttering
- MUSC Hollings Cancer Center
-
Hovedetterforsker:
- Eric Wallen, MD
-
Ta kontakt med:
- Sarah Helpinstill
- Telefonnummer: 843-792-9300
- E-post: sah277@musc.edu
-
Murrells Inlet, South Carolina, Forente stater, 29576
- Har ikke rekruttert ennå
- Tidelands Health Urology
-
Ta kontakt med:
- Barbara Roe
- E-post: broe@tidelandshealth.org
-
Hovedetterforsker:
- Lauren Cooley, MD
-
-
Texas
-
Austin, Texas, Forente stater, 78745
- Rekruttering
- Urology Austin
-
Hovedetterforsker:
- Brian Mazzarella, MD
-
Ta kontakt med:
- Jennifer Penshorn, RN
- E-post: jennifer.penshorn@urologyaustin.com
-
Underetterforsker:
- David Cuellar, MD
-
Underetterforsker:
- Eric Giesler, MD
-
Underetterforsker:
- Varun Sundaram, MD
-
Underetterforsker:
- Carl Bischoff, MD
-
Austin, Texas, Forente stater, 78705
- Rekruttering
- Midtown Urology
-
Ta kontakt med:
- Andrew Barger
- Telefonnummer: 512-451-7935
- E-post: APBarger@cimplify.net
-
Hovedetterforsker:
- Michael Trotter, MD
-
Underetterforsker:
- Tyler McClintock, MD
-
Dallas, Texas, Forente stater, 75231
- Rekruttering
- Urology Clinics of North Texas
-
Hovedetterforsker:
- Gregory Thoreson, MD
-
Ta kontakt med:
- Jacquelyn Ward
- E-post: jward@urologyclinics.com
-
-
Virginia
-
Alexandria, Virginia, Forente stater, 22311
- Har ikke rekruttert ennå
- Potomac Urology
-
Hovedetterforsker:
- Shawn Marhamati, MD
-
Underetterforsker:
- Nilay Gandhi, MD
-
Ta kontakt med:
- Zoe Goldstein
- E-post: zoe.goldstein@potomacurology.com
-
-
Wisconsin
-
Sheboygan, Wisconsin, Forente stater, 53081
- Har ikke rekruttert ennå
- Advocate Aurora Research Institute
-
Hovedetterforsker:
- Jeffrey Tomasini, MD
-
Ta kontakt med:
- Mary Theodoroff
- E-post: mary.theodoroff@aah.org
-
-
-
-
-
Shatin, Hong Kong
- Har ikke rekruttert ennå
- Chinese University of Hong Kong
-
Ta kontakt med:
- Becky Lau
- E-post: beckylau@surgery.cuhk.edu.hk
-
Hovedetterforsker:
- Jeremy Teoh, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Biological male with age ≥ 45 years at the time of consent
- Biopsy positive Grade Group 2 prostate cancer or biopsy positive Grade Group 1 MRI visible lesion (PI-RADS/Likert ≥ 3)
- First prostate cancer diagnoses within 18 months (545 days) of consent
- Are candidates for active surveillance
- Clinical Stage ≤ T2c
- PSA < 15 ng/ml
- Prostate volume ≥25 ml
Exclusion Criteria:
- Any prior or current local or systemic treatment for prostate cancer, including but not limited to surgery, radiation therapy (external or brachytherapy), tissue ablation, hormone therapy or chemotherapy.
- Patients with previous surgical or minimally invasive treatment of benign prostatic hyperplasia within the prior 3 months of study treatment.
- Evidence of lymph node, bone metastasis, extracapsular extension or seminal vesicle invasion.
- Patient is unwilling to accept a blood transfusion if required.
- Any condition or history of illness or surgery that may pose an additional risk to patients undergoing the Aquablation or radical prostatectomy procedure such as:
5a. Medical conditions that preclude the use of anesthesia; 5b. Any condition or history of active rectal inflammatory bowel disease or other factors which might increase the risk of rectal injury (i.e. fistula formation); 5c. Patient is unable to stop anticoagulants or antiplatelet agents prior to study treatment per standard of care; 5d. Any other condition or history of infection, illness or surgery that in the opinion of the investigator might affect the outcome of the study procedure, study conduct, and study results; or pose additional risks to the patient (e.g., other cancer, active urethral stricture disease).
6. Patients who are unable to provide informed consent due to cognitive impairment, legal status (such as incarceration), or other factors limiting autonomy or unwilling or unable to follow study instructions including randomization and complete all required study visits through 10 years. This includes individuals with severe cognitive disabilities, those under legal guardianship, or those currently incarcerated.
7. Patient currently participating in other studies unless approved by Sponsor in writing.
8. More than one complete biopsy beyond the diagnostic biopsy comprising both a systematic biopsy and biopsy of any MRI visible lesion (PI-RADS/Likert ≥ 3).
9. GG2 disease with PSA ≥ 10 OR stage ≥ T2b OR ≥ 50% of biopsy cores positive (multiple cores taken from any MRI visible lesion are counted as one continuous core).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Aquablation Therapy
The Aquablation Therapy arm will receive Aquablation with either the AQUABEAM Robotic System or HYDROS Robotic System |
The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy. |
|
Aktiv komparator: Active Surveillance
The active surveillance arm will receive standard-of-care for prostate cancer management. |
Active surveillance is a management strategy for men with low- and favorable intermediate-risk localized prostate cancer that involves close monitoring with curative intent, reserving treatment for evidence of disease progression. Monitoring typically includes serial PSA testing, periodic prostate MRI, and repeat biopsies at scheduled intervals, with intervention triggered by evidence of disease progression. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Freedom from GG ≥ 2
Tidsramme: 12 Months
|
12 Months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Freedom from persistent or increased MRI suspicion AND additional prostate cancer treatment
Tidsramme: 3 Years
|
3 Years
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Genitale neoplasmer, hanner
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kjønnssykdommer, mannlige
- Prostata sykdommer
- Mannlige urogenitale sykdommer
- Prostatiske neoplasmer
- Health Services Administration
- Kvalitet på helsehjelpen
- Resultatvurdering, helsehjelp
- Resultat og prosessvurdering, helsehjelp
- Vakelig venting
Andre studie-ID-numre
- CSP0005 - AS Sub-study
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .